Introduction {#s1}
============

Myocardial necrosis is accompanied by the release of cardiac troponin (cTn) into the bloodstream, which makes cTn the preferred biomarker for the diagnosis of acute myocardial infarction (AMI) [@pone.0079280-Thygesen1]. Interestingly, elevated cTn concentrations are not restricted to AMI, but are also observed in a wide range of cardiac and non-cardiac pathologies e.g. renal failure, pulmonary embolism, myocarditis and congestive heart failure (an extensive list has been published in [@pone.0079280-Agewall1], [@pone.0079280-Kelley1]). In all these pathological settings elevated cTn concentrations are consistently associated with poor prognosis [@pone.0079280-Saunders1]--[@pone.0079280-Omland1]. An intriguing example of non-AMI related cTn release in healthy subjects occurs after moderate and highly intensive endurance exercise such as marathons, cycling events and long-distance walking [@pone.0079280-Neumayr1]--[@pone.0079280-Neumayr2]. cTn levels in blood rise quickly during exercise, and unlike AMI, they return quickly to normal in approximately 24--48 hours [@pone.0079280-Middleton1], [@pone.0079280-Howatson1], [@pone.0079280-Scherr1]. To date it has not been clarified whether exercise-induced cTn release is a physiologic or pathologic phenomenon. There is no epidemiological evidence thus far that links the magnitude of exercise-induced cTn release to poor prognosis. The faster kinetics of exercise-induced cTn release, and the possible presence of a cytosolic unbound cTn fraction in the cardiomyocyte [@pone.0079280-Katus1], triggered the postulation of a distinct release model for cTn during exercise, unrelated to myocardial cell death [@pone.0079280-Hickman1]. This hypothetical model states that exercise-induced cTn release could be attributed to increased cardiomyocyte permeability (through mechanical stress or increased production of oxidative radicals) and subsequent early troponin release from a cytosolic cTn pool, possibly through membrane blebbing [@pone.0079280-Hickman1], [@pone.0079280-Shave1]. This atypical model of benign cTn release was coined the "reversible injury hypothesis". It challenges the dogma that increased cTn concentrations always reflect cell death, and unites two apparently incompatible observations: 1) the frequent occurrence of exercise-induced cTn release [@pone.0079280-Shave2], and 2) the limited cardiomyocyte regenerative capacity [@pone.0079280-Bergmann1]. This hypothesis however, has been opposed by a number of observations that warrant prudence before classifying all exercise-induced cTn rises as benign. First, the most pronounced post-exercise cTn concentrations have been observed in the least trained subjects [@pone.0079280-Mehta1]. Second, baseline cTn levels, which are robust predictors of cardiovascular morbidity and mortality in virtually every patient group investigated, explained up to 80% of the cTn variation after exercise [@pone.0079280-Klinkenberg1]. Finally, a strong correlation has been observed between post-exercise cTn concentrations and short-term right ventricular functional impairment [@pone.0079280-LaGerche1]. Over time, repetitive strain on the right ventricle may lead to chronic structural changes, as demonstrated by a high prevalence of chronic structural changes in athletes with the highest cumulative exposure to endurance competition [@pone.0079280-Heidbuchel1]--[@pone.0079280-Wilson1].

The identification of the biological mechanism that underlies exercise-induced cTn release is an active and relevant topic of discussion [@pone.0079280-Shave1]. Oxidative stress associated with prolonged exercise has been proposed to contribute to cTn release [@pone.0079280-Nie1], [@pone.0079280-Whyte1]. If true, supporting endogenous defense systems with additional doses of antioxidants could therefore be an important strategy to examine the role of oxidative stress as a mechanism for exercise-induced cTn release. Therefore, we subjected male trained cyclists to a laboratory based standardized exercise protocol before and after 4 weeks of astaxanthin (a potent cartenoid antioxidant) or placebo supplementation. We hypothesized that astaxanthin supplementation attenuates oxidative stress, inflammation and muscle damage following cycling exercise and hence reduces exercise-induced cardiac troponin release.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

This study complies with the Declaration of Helsinki and was approved by the Institutional Review Board and Ethics Committee at Maastricht University Medical Center. All participants gave written informed consent. This study was registered at clinicaltrials.gov as NCT01241877. The protocol for this trial and supporting CONSORT checklist are available as supporting information; see [Checklist S1](#pone.0079280.s003){ref-type="supplementary-material"} and [Protocol S1](#pone.0079280.s002){ref-type="supplementary-material"}.

Trial Design {#s2b}
------------

The study was designed as a double-blind, placebo-controlled randomized parallel group trial. Thirty-two healthy male volunteers were recruited from 01-12-2010 till 01-06-2011 via local cycling clubs. We included healthy, young (age between 18 and 30 years), endurance-trained male cyclists, with a training history of more than 3 sessions per week for more than one year. The study was conducted between 01-01-2011 and 01-11-2011 at the Department of Human Movement Sciences at Maastricht University Medical Center. All subjects were competitive cyclists or triathletes who had been involved in regular cycling training (more than 3 sessions per week with 11±5 hours per week) for at least two years.

Study Protocol {#s2c}
--------------

The study was designed to examine the effect of 4 weeks of astaxanthin supplementation on exercise-induced cTn release. This study is part of a greater randomized trial examining the impact of astaxanthin supplementation on muscle metabolism and exercise performance, as primary outcome measures [@pone.0079280-Res1]. Briefly, subjects visited our laboratory on four occasions, two of which were scheduled prior to the start of the main experimental period. The first visit consisted of an incremental cycling exercise test to exhaustion to determine subjects' maximal workload capacity (W~max~) and maximum oxygen uptake (VO~2\ max~). The second visit consisted of a familiarization test that was identical in design as the main experimental test days. The actual experimental period (visit 3 and 4) consisted of two identical standardized cycling trials, separated by a 4 week supplementation period with astaxanthin or placebo. The pre- and post-supplementation trials were performed on the same time and day of the week for each subject. On each test day, subjects reported to the laboratory at 08.00 after an overnight fast. A Teflon catheter (Baxter, Utrecht, the Netherlands) was inserted into an antecubital vein for blood sampling. The exercise protocol consisted of 60 min steady-state moderate intensity exercise (50% W~max~) followed by a validated time-trial [@pone.0079280-Jeukendrup1], in which athletes performed a set amount of work at maximal performance for about ≈ 60 min. Blood samples were obtained at baseline, at 60 min of cycling and immediately post-exercise (≈ 120 min).

Supplementation Protocol {#s2d}
------------------------

Participants were randomly assigned in a double-blind fashion to receive either 20 mg/day of astaxanthin or placebo for 4 weeks. Randomization was performed by a random number generator ([www.random.org](http://www.random.org)). Astaxanthin is a xanthophyll carotenoid pigment with potent antioxidative and anti-inflammatory capacities and has previously been shown to attenuate exercise-induced oxidative damage in mouse skeletal and cardiac muscle [@pone.0079280-Aoi1], [@pone.0079280-Iwamoto1]. The astaxanthin supplementation consisted of a natural astaxanthin extract from the microalga *Haematococcus pluvialis* (80 mg of 5% astaxanthin) dissolved in sun flower oil in gelatin capsules with added vitamin C (60 mg per capsule) and vitamin E (10 mg per capsule) (BioReal, Gustavsberg, Sweden). Participants ingested 2 capsules (4 mg astaxanthin/capsule) with breakfast and 3 capsules with dinner throughout the 4-week intervention period. The placebo supplement was externally identical to the astaxanthin capsule, without the phytonutrient content. The placebo group followed the same supplementation protocol as the astaxanthin group. The supplementation was assigned by an independent investigator, so that both the subjects and investigators were blinded to the treatment. Supplementation compliance was assessed by the number of pills that were left over in the pill bottle after the supplementation period.

Physical Activity and Dietary Standardization {#s2e}
---------------------------------------------

During the study, subjects were allowed to consume their normal diets but were instructed to refrain from astaxanthin-rich foods such as salmon, lobster, and shrimp. All subjects were also instructed to refrain from physical exercise for two days before each test day. In addition, we asked subjects to record their food intake for two days before the pre-supplementation test day and to replicate their food intake two days before the post-supplementation test day. All subjects received a standardized dinner the evening prior to each experimental test day (62±4 kJ·kg bodyweight^−1^, consisting of 50 energy percent (En%) carbohydrate, 10 En% protein, and 40 En% fat).

Biochemical Analyses {#s2f}
--------------------

Plasma and serum samples were stored at −80°C until analysis. Serum cardiac troponin T (cTnT) was measured using the high-sensitivity cTnT assay (Roche Diagnostics) on the Elecsys 2010 using lot no. 167650. The measuring range of this assay is 3--10,000 ng/L, with a 99^th^ percentile in apparently healthy individuals at 14 ng/L, which is clinically employed to diagnose AMI [@pone.0079280-Giannitsis1]. Serum creatine kinase (CK) was measured on Roche Cobas 6000 analyzer. Serum high-sensitivity C-reactive protein (hsCRP) was measured on the BN Prospec (Siemens). Plasma carotenoid concentrations and antioxidant markers (trolox equivalent antioxidant capacity (TEAC), uric acid, and malondialdehyde (MDA)) have been measured in the setting of a previous study and reported accordingly [@pone.0079280-Res1].

Statistical Analysis {#s2g}
--------------------

To be able to detect a 10% reduction in exercise-induced cTn release (from 7.0±1.4 to 6.3±1.3 ng/L) due to astaxanthin, with a two-sided significance level of 5% and 80% power, a total of 32 subjects were recruited. No intervention has been reported that effective reduces exercise-induced cTn release. The effect size of 10% was therefore derived from the antioxidant-induced reduction of skeletal muscle damage after exercise [@pone.0079280-Luden1], [@pone.0079280-Zoppi1]. In these studies 20--30% reductions of CK levels were obtained through antioxidant supplementation. Assuming a similar mechanism and effect size in cardiac muscle, we felt that a \<10% reduction would exclude a major role for antioxidants in this setting. The Kolmogorov-Smirnov test was used to evaluate the normality of the data. Participant characteristics are presented as the mean ± SD, biochemical parameters are shown as median and interquartile range. Paired data was tested using the Mann Whitney U test, non-paired data via the Wilcoxon Signed-Rank test. The incremental area under the curve (iAUC) was used as a summary measure for exercise-induced cTnT release. The effect of antioxidant supplementation was assessed by analysis of variance (ANOVA), using the iAUC at pre-supplementation as covariate. Statistical analysis was performed using SPSS, version 18.0.

Results {#s3}
=======

Participants Characteristics {#s3a}
----------------------------

A detailed flow of the trial is described in [Figure 1](#pone-0079280-g001){ref-type="fig"}. Thirty-two well-trained cyclists were included in the study. One subject in the placebo group left the study prematurely for medical reasons, unrelated to the study protocol. Subjects' baseline characteristics are shown in [Table 1](#pone-0079280-t001){ref-type="table"}. No differences in age, weight, maximum O~2~ uptake, maximum workload capacity or the average hours of training per week were observed between the placebo (n = 15) and astaxanthin group (n = 16).

![Flow chart of the trial.](pone.0079280.g001){#pone-0079280-g001}

10.1371/journal.pone.0079280.t001

###### Participants characteristics.

![](pone.0079280.t001){#pone-0079280-t001-1}

                                             All participants   Placebo    Antioxidant
  ----------------------------------------- ------------------ ---------- -------------
  Age (years)                                    24.7±4.7       25.0±5.5    24.5±3.9
  Weight (kg)                                    72.9±7.2       73.0±8.5    72.9±6.1
  Maximum O~2~ uptake (mL·kg^−1^·min^−1^)        60.2±4.8       59.5±5.4    60.9±4.3
  Maximum workload (W·kg^−1^)                    5.4±0.5        5.3±0.5      5.5±0.5
  Training (hours/week)                          10.9±4.2       10.5±4.9    11.2±3.5

Data are presented as mean ± SD.

Astaxanthin Supplementation {#s3b}
---------------------------

In the placebo group, plasma astaxanthin concentrations were undetectable throughout the study. In the astaxanthin group, plasma astaxanthin concentrations were significantly increased from non-detectable values to 175±86 µg·kg^−1^. There were no differences in other cartenoid intake within or between groups during the study.

Astaxanthin does not Reduce the Magnitude of Exercise-induced Cardiac Troponin Release {#s3c}
--------------------------------------------------------------------------------------

The pre-supplementation cycling trial induced a significant increase in cTnT, from overall median cTnT 3.2 (IQR 3.0--4.2) to 4.7 ng/L (IQR 3.7--6.7) immediately post-exercise (p\<0.001) ([Figure 2A](#pone-0079280-g002){ref-type="fig"}). Four weeks of astaxanthin supplementation did not affect baseline cTnT concentrations compared to placebo supplementation (median 3.0 (IQR 3.0--4.5) versus 3.7 ng/L (IQR 3.0--4.6)) (p = 0.63). The post-supplementation cycling trial resulted in a significant increase from median cTnT 3.0 (IQR 3.0--4.5) to 5.7 ng/L (IQR 3.0--6.9) in the placebo group ([Figure 2B](#pone-0079280-g002){ref-type="fig"}), and from median cTnT 3.7 (IQR 3.0--4.7) to 4.8 ng/L (IQR 3.6--6.9) in the astaxanthin group, immediately post-exercise ([Figure 2C](#pone-0079280-g002){ref-type="fig"}) (both p\<0.01). Despite the increase in basal astaxanthin concentrations, there were no differences between groups in the post-supplementation incremental area under the cTnT curve (p = 0.24). Furthermore, there was no significant association between the supplementation-induced astaxanthin concentration and exercise-induced cTn release (data not shown).

![cTnT, CK and hsCRP concentrations during the pre- and post-supplementation exercise trials.\
A, D, G. Whole group cTnT, CK and hsCRP concentrations during the pre-supplementation exercise trials. B, E, H. cTnT, CK and hsCRP concentrations in the placebo group measured during the pre- and post-supplementation cycling trials. C, F, I. cTnT, CK and hsCRP concentrations in the astaxanthin group during the pre- and post-supplementation trials. \*\*\*denotes a significant increase from baseline (P\<0.001). Values are median and interquartile range.](pone.0079280.g002){#pone-0079280-g002}

Astaxanthin does not Improve Antioxidant Capacity in Highly Trained Individuals {#s3d}
-------------------------------------------------------------------------------

Antioxidant capacity markers including trolox equivalent antioxidant capacity (TEAC), uric acid, and malondialdehyde (MDA) did not differ between the pre- and post-supplementation exercise trials or between groups. Markers of exercise-induced skeletal muscle damage (CK) ([Figure 2](#pone-0079280-g002){ref-type="fig"}, D--F) and inflammation (hsCRP) ([Figure 2](#pone-0079280-g002){ref-type="fig"}, G--I) were equally unaffected by astaxanthin supplementation. Furthermore, no evident relationship was detected between any of the antioxidant capacity markers and post-exercise cTnT concentrations ([Figure S1](#pone.0079280.s001){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In the present study we demonstrate that 4 weeks antioxidant supplementation did not improve antioxidant capacity, and did not reduce exercise-induced cTn release in well-trained individuals.

Intensive physical activity is characterized by an increase in oxygen consumption with concomitant production of reactive oxygen species. In the setting of AMI, generation of reactive oxygen species during the reintroduction of blood flow to a previously ischemic area, is a well established contributor to myocardial reperfusion injury and cTn release [@pone.0079280-Park1]. We hypothesized that a similar mechanism would apply in the setting of exercise-induced cTn release, and that oxidative stress associated with endurance exercise causes reversible or irreversible damage to cardiomyocytes with consequent release of cTnT.

The lack of any improvement in antioxidant capacity in the present study was unlikely due to non-compliance of the subjects. Compliance, estimated by pill-counting was \>90% in 28 out of 31 subjects. Adequate compliance was also evident from strongly increased plasma astaxanthin concentrations. Furthermore, the effect of astaxanthin supplementation was not masked by differences in the total carotenoid intake during the experimental period or between groups. In previous studies, prolonged astaxanthin supplementation (12 weeks, 8 mg/day [@pone.0079280-Karppi1] or 12 weeks, 20 mg/day [@pone.0079280-Choi1] improved total antioxidant capacity, attenuated MDA and lipid peroxidation. Possibly the highly trained state of our participants, which is associated with already substantially elevated endogenous antioxidant capacity [@pone.0079280-GomezCabrera1], [@pone.0079280-Radak1], precluded an additional improvement through antioxidant supplementation.

In line with the absence of any effect of astaxanthin on antioxidant capacity, no significant reduction of exercise-induced cTn release were observed in subjects following 4 weeks of antioxidant supplementation. To date, one previous study addressed the hypothesis that antioxidant supplementation (tart cherry juice) reduces exercise-induced cTn release in humans, and concluded that 5 days of antioxidant supplementation did not attenuate circulating cTn following a marathon run [@pone.0079280-Howatson1], [@pone.0079280-Howatson2]. Our study complements this work and deals with some limitations of the original report related to power, duration of antioxidant supplementation, and study design: we extended the period of antioxidant supplementation, increased the number of study subjects and applied a pre-post test design that allows each subject to act as its own control. Our approach circumvents power problems that may arise from the high between-person variation in exercise-induced cTn release [@pone.0079280-Klinkenberg1], and exploits the good reproducibility and low within-person variation of cTn release during two identical exercise bouts [@pone.0079280-Klinkenberg1].

In conclusion, despite substantial increases in plasma astaxanthin concentrations, astaxanthin supplementation did not improve antioxidant capacity in highly trained cyclists. Accordingly, exercise-induced cTnT concentrations were not affected by astaxanthin supplementation.

Supporting Information {#s5}
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**Relation between exercise-induced cTnT concentrations and markers of antioxidant capacity.** Post-exercise cTnT concentrations during the post-supplementation trial are plotted against post-supplementation concentrations of TEAC (A), MDA (B) and Uric Acid (C).
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